Skin treatment device

Information

  • Patent Grant
  • 11090473
  • Patent Number
    11,090,473
  • Date Filed
    Monday, June 4, 2018
    6 years ago
  • Date Issued
    Tuesday, August 17, 2021
    3 years ago
Abstract
A new minimally invasive surgical approach is proposed that contemplates a method and apparatus for tightening lax skin without visible scarring via a device in various surgical procedures such as plastic surgery procedures. In some embodiments, the device is a single use disposable instrument. This approach circumvents surgically related scarring and the clinical variability of electromagnetic heating of the skin and performs small multiple pixilated resections of skin as a minimally invasive alternative to large Plastic surgical resections of skin. This approach can also be employed in areas of the body that are currently off limits to plastic surgery due to the visibility of the surgical scar. In addition, the approach can perform a skin grafting operation by harvesting the transected incisions of skin from a tissue site of a donor onto a skin defect site of a recipient with reduced scarring of the patient's donor site.
Description
BACKGROUND

The aging process is most visibly depicted by the development of dependent skin laxity. This life long process may become evident as early as the third decade of life and will progressively worsen over subsequent decades. Histological research has shown that dependant stretching or age related laxity of the skin is due in part to progressive dermal atrophy associated with a reduction of skin tensile strength. When combined with the downward force of gravity, age related dermal atrophy will result in the two dimensional expansion of the skin envelope. The clinical manifestation of this physical-histological process is redundant skin laxity. The most affected areas are the head and neck, upper arms, thighs, breasts, lower abdomen and knee regions. The most visible of all areas is the head and neck. In this region, prominent “turkey gobbler” laxity of neck and “jowls” of the lower face are due to an unaesthetic dependency of skin in these areas. The frequency and negative societal impact of this aesthetic deformity has prompted the development of the “Face Lift” surgical procedure. Other related plastic surgical procedures in different regions are the Abdominoplasty (Abdomen), the Mastopexy (Breasts), and the Brachioplasty (Upper Arms). Some of the inherent adverse features of these surgical procedures are post-operative pain, scarring and the risk of surgical complications. Even though the aesthetic enhancement of these procedures is an acceptable tradeoff to the significant surgical incisions required, permanent and extensive scarring is always an incumbent part of these procedures. For this reason, Plastic Surgeons design these procedures to hide the extensive scarring around anatomical borders such as the hairline (Facelift), the inframmary fold (Mastopexy) and the inguinal crease (Abdominoplasty). However, other skin laxity regions such as the Suprapatellar (upper-front) knee are not amendable to Plastic Surgical resections due to the poor tradeoff with a more visible surgical scar. Recently, electromagnetic medical devices that create a reverse thermal gradient (i.e., Thermage) have attempted with variable success to tighten skin without surgery. At this time, these electromagnetic devices are best deployed in patients with a moderate amount of skin laxity due to the limitations of electromagnetic devices and potential side effects of surgery.


The foregoing examples of the related art and limitations related therewith are intended to be illustrative and not exclusive. Other limitations of the related art will become apparent upon a reading of the specification and a study of the drawings.





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1(a)-(c) depict examples of a full rolling/rotating pixel drum/cylinder applicable to a skin surface for tightening.



FIGS. 2(a)-(d) depict examples of dissected internal structure of a half drum depicted in FIGS. 1(a)-(d).



FIGS. 3(a)-(d) depict examples of an oscillating flat array of scalpets and blade either powered electrically or deployed manually (unpowered).



FIG. 4 depicts an example of a cadaver dermal matrix cylindrical transected similar in size to the harvested skin pixel grafts to provide histological alignment of the pixilated graft into the cadaver dermal framework.



FIG. 5 depicts example of a drum-based drug delivery device being applied to the skin surface for drug injection.



FIG. 6(a)-(c) depict examples of a drug delivery device based on flat array of needles being applied to the skin surface for drug injection.





DETAILED DESCRIPTION OF EMBODIMENTS

The approach is illustrated by way of example and not by way of limitation in the figures of the accompanying drawings in which like references indicate similar elements. It should be noted that references to “an” or “one” or “some” embodiment(s) in this disclosure are not necessarily to the same embodiment, and such references mean at least one.


A new minimally invasive surgical approach is proposed that contemplates a method and apparatus for tightening lax skin without visible scarring via a device in various surgical procedures such as plastic surgery procedures. In some embodiments, the device is a single use disposable instrument. This approach circumvents surgically related scarring and the clinical variability of electromagnetic heating of the skin and performs small multiple pixilated resections of skin as a minimally invasive alternative to large Plastic surgical resections of skin. This approach can also be employed in areas of the body that are currently off limits to plastic surgery due to the visibility of the surgical scar. In addition, the approach can perform a skin grafting operation by harvesting the transected incisions of skin from a tissue site of a donor onto a skin defect site of a recipient with reduced scarring of the patient's donor site.


For many patients who have age related skin laxity (for non-limiting examples, neck and face, arms, axillas, thighs, knees, buttocks, abdomen, bra line, ptosis of the breast), the minimally invasive surgical approach performs pixilated transection/resection of excess skin, replacing Plastic Surgery with its incumbent scarring. Typically, the procedure will be performed in an office setting under a local anesthetic with minimal perioperative discomfort. In comparison to a prolonged healing phase from plastic surgery, only a short recovery period will be required and the only recovery requirement will be the need to wear a support garment over the treatment area for 5 days. There will be little or no pain associated with the procedure. The small (½ mm tolmm) intradermal circular skin defects will be closed with the application of an adherent Flexan (3M) sheet. Functioning as a large butterfly bandage, the Flexan sheet can be pulled in a direction (“vector”) that maximizes the aesthetic contouring of the treatment area. A compressive elastic garment will be applied over the dressing to further assist aesthetic contouring. After completion of the initial healing phase, the multiplicity of small linear scars within the treatment area will not be visibly apparent. It is also predicted that additional skin tightening will occur subsequently over several months due to the delayed wound healing response. Other potential applications include the treatment of Snoring/Sleep apnea, Orthopedics/Physiatry, Vaginal Tightening and tightening of gastrointestinal sphincters. During recovery, the treatment area is covered with a Flexan dressing and a compressive garment that promotes the wound healing process in the most effective direction.


Device for Skin Treatment



FIGS. 1(a)-(c) depict examples of a full rolling/rotating pixel drum/cylinder 100 applicable to the skin surface for tightening. Although the diagrams depict components as functionally separate, such depiction is merely for illustrative purposes. It will be apparent that the components portrayed in this figure can be arbitrarily combined or divided into separate hardware components.


Referring now to FIGS. 1(a)-(c), FIG. 1(a) depicts an example of rolling pixel drum 100, FIG. 1(b) depicts an example of a rolling pixel drum 100 assembled on a handle, and FIG. 1(c) depicts an example of a rolling pixel drum 100 being applied to the skin surface for tightening. FIGS. 2(a)-(d) further depict examples of dissected internal structure of a half drum depicted in FIGS. 1(a)-(d).


As with other pixel devices, the geometry of the pixel drum 100 can be a variety of shapes without limitation i.e., circular, semicircular, elliptical, square, flat, or rectangular. In some embodiments, the pixel drum 100 is supported by an axel/handle assembly 102 and rotated around a drum rotational component 104 powered by, e.g., an electric motor. In some embodiments, the pixel drum 100 can be placed on stand (not shown) when not in use, wherein the stand can also function as a battery recharger for the powered rotational component of the drum or the powered component of the syringe plunger. In some embodiments, a vacuum (not shown) can be applied to the skin surface of the pixel drum 100 and outriggers (not shown) can be deployed for tracking and stability of the pixel drum 100.


In some embodiments, the pixel drum 100 incorporates an array of scalpets 106 on the surface of the drum 100 to create small multiple (e.g., ½ mm to 1 mm) circular incisions referred to herein as skin plugs. In some embodiments, the border geometry of the scalpets can be designed to reduce pin cushioning (“trap door”) while creating the skin plugs. The perimeter of each skin plug can also be lengthened by the scalpets to, for a non-limiting example, a, semicircular, elliptical, or square-shaped skin plug instead of a circular-shaped skin plug. In some embodiments, the length of the scalpets 106 may vary depending upon the thickness of the skin area selected by the surgeon for skin grafting purposes, i.e., partial thickness or full thickness.


When the drum 100 is applied to a skin surface, a blade 108 placed internal of the drum 100 transects the base of each skin plug created by the array of scalpets, wherein the internal blade 108 is connected to the central drum axel/handle assembly 102 and/or connected to outriggers attached to the central axel assembly 102. In some alternative embodiments, the internal blade 108 is not connected to the drum axel assembly 102 where the base of the incisions of skin is transected. In some embodiments, the internal blade 108 of the pixel drum 100 may oscillate either manually or be powered by an electric motor. Depending upon the density of the circular scalpets on the drum, a variable percentage of skin can be transected. It is predicted that up to 50% of the skin's surface area can be transected within an area of excessive skin laxity.


In some embodiments, an added pixel drum harvester 112 is placed inside the drum 100 to perform a skin grafting operation by harvesting and aligning the transected/pixilated skin incisions/plugs (pixel graft) from tissue of a pixel donor onto an adherent membrane 110 lined in the interior of the pixel drum 100. A narrow space is created between the array of scalpets 106 and the adherent membrane 110 for the internal blade 108.


In some embodiments, the blade 108 is placed external to the drum 100 and the scalpet array 106 where the base of the incised circular skin plugs is transected. In some embodiments, the external blade 108 is connected to the drum axel assembly 102 when the base of the incisions of skin is transected. In some alternative embodiments, the external blade 108 is not connected to the drum axel assembly 102 when the base of the incisions of skin is transected. The adherent membrane 110 that extracts and aligns the transected skin segments onto the membrane 110, which is later placed over a skin defect site of a patient. In some embodiments, blade 108 (either internal or external) can be a fenestrated layer of blade aligned to the scalpet array 106.


In some embodiments, the conformable adherent membrane 110 can be semi-porous to allow for drainage at a recipient skin defect when the membrane with the aligned transected skin segments is extracted from the drum and applied as a skin graft. In some embodiments, the adherent semi-porous drum membrane 110 can also have an elastic recoil property to bring the transected/pixilated skin plugs together for grafting onto the skin defect site of the recipient, i.e., the margins of each skin plug can be brought closer together as a more uniform sheet after the adherent membrane with pixilated grafts extracted from the drum 100. In some embodiments, the adherent semi-porous drum membrane 110 can also be expandable to cover a large surface area of the skin defect site of the recipient. In some embodiments, a sheet of adhesive backer 111 can be applied between the adherent membrane 110 and the drum harvester 112. The drum array of scalpets 106, blade 108, and adherent membrane 110 can be assembled together as a sleeve onto a preexisting drum 100 as shown in FIGS. 2(c)-(d).


In some embodiments, the internal drum harvester 112 of the pixel drum 110 is disposable and replaceable. Limit and/or control the use of the disposable components can be accomplished by means that includes but is not limited to electronic, eprom, mechanical, durability. The electronic and/or mechanical records and/or limits of number of drum rotations for the disposable drum as well as the time of use for the disposable drum can be recorded, controlled and/or limited either electronically or mechanically.


In some embodiments, an oscillating flat array of scalpets and blade as shown in FIGS. 3(a)-(d) either powered electrically or deployed manually (unpowered) can be used for skin tightening as alternative to the drum/cylinder depicted in FIGS. 1(a)-(c) and 2(a)-(d). Here, blade 108 can be a fenestrated layer of blade aligned to the scalpet array 106. FIGS. 3(a)-(b) depict top and bottom views of the flat array where the instrument handle 102 is separated from the blade handle 103 and the adherent membrane 110 can be peeled away from the adhesive backer 111. FIG. 3(c) depict a close-up view of the flat array when the array of scalpets 106, blades 108, adherent membrane 110 and the adhesive backer 111 are assembled together. As assembled, the flat array of scalpets can be metered to provide a uniform harvest or a uniform resection. In some embodiments, the flat array of scalpets may further include a feeder component 115 for the adherent harvesting membrane 110 and adhesive backer 111 as shown in FIG. 3(d).


In another skin grafting embodiment, the pixel graft is placed onto an irradiated cadaver dermal matrix (not shown). When cultured onto the dermal matrix, a graft of full thickness skin is created for the patient that is immunologically identical to the pixel donor. In some embodiments, the cadaver dermal matrix can also be cylindrical transected similar in size to the harvested skin pixel grafts to provide histological alignment of the pixilated graft into the cadaver dermal framework as shown in FIG. 4. In some embodiments, the percentage of harvest of the donor site can be determined in part by the induction of a normal dermal histology at the skin defect site of the recipient as shown in FIG. 4, i.e., a normal (smoother) surface topology of the skin graft is facilitated. With either the adherent membrane or the dermal matrix embodiment, major advantage of the pixel drum harvester includes the ability to harvest a large surface area for grafting with visible scarring of the patient's donor site significantly reduced or eliminated.


In some embodiments, the pixel drum 100 may evoke cellular and/or extracellular responses that are obligatory to the clinical outcomes achieved and a physical reduction of the skin surface area may occur due to the transected/pixilated skin, i.e., creation of the skin plugs. In addition, a subsequent tightening of the skin is predicted due to the delayed wound healing response. Each skin pixilation may initiate the obligate wound healing sequence in multiple phases:

    • The first phase of this sequence is the inflammatory phase in which degranulation of mast cells release histamine into the “wound”. Histamine release may evoke dilatation of the capillary bed and increase vessel permeability into the extracellular space. This initial wound healing response occurs within the first day and will be evident as erythema on the skin's surface.
    • The second phase (of Fibroplasia) commences within 4-5 days of “wounding”. During this phase, there is migration and mitotic multiplication of fibroblasts. Fibroplasia of the wound has two key features: the deposition of neocollagen and the myofibroblastic contraction of the wound. Histologically, the deposition of neocollagen can be identified microscopically as compaction and thickening of the dermis. Although this is a static process, the tensile strength of the wound significantly increases. The other feature of Fibroplasia is a dynamic physical process that results in a three dimensional contraction of the wound. This component feature of Fibroplasia is due to the active cellular contraction of myofibroblasts. Morphologically, myoblastic contraction of the wound will be visualized as a two dimensional tightening of the skin surface. Overall, the effect of Fibroplasia will be dermal contraction along with the deposition of a static supporting scaffolding of neocollagen with a tightened framework. The clinical effect can be seen as a delayed tightening of skin with smoothing of skin texture over several months. The clinical endpoint is a more youthful appearing skin envelope of the treatment area.
    • A third and final phase of the delayed wound healing response is maturation. During this phase there is a strengthening and remodeling of the treatment area due to an increased cross-linkage of the collagen fibril matrix (of the dermis). This final stage commences with 6 to 12 months after “wounding” and may extend for at least 1-2 years. Small pixilated resections of skin should preserve the normal dermal architecture during this delayed wound healing process without the creation of an evident scar that typically occurs with a larger surgical resection of skin. Lastly, there is a related stimulation and rejuvenation of the epidermis from the release of epidermal growth hormone. The delayed wound healing response can be evoked, with scar collagen deposition, within tissues (such as muscle or fat) with minimal pre-existing collagen matrix.


Other than tightening skin for aesthetic purposes, the pixel drum 100 described above may have additional medically related applications. In some embodiments, the pixel drum 100 can transect a variable portion of any soft tissue structure without resorting to a standard surgical resection. More specifically, the reduction of an actinic damaged area of skin via the pixel drum 100 should reduce the incidence of skin cancer. For the treatment of sleep apnea and snoring, a pixilated mucosal reduction (soft palate, base of the tongue and lateral pharyngeal walls) via the pixel drum 100 would reduce the significant morbidity associated with more standard surgical procedures. For birth injuries of the vaginal vault, pixilated skin and vaginal mucosal resection via the pixel drum 100 would reestablish normal pre-partum geometry and function without resorting to an A&P resection. Related female stress incontinence could also be corrected in a similar fashion.


Drug Delivery Device


For the most part, the parenteral delivery of drugs is still accomplished from an injection with a syringe and needle. To circumvent the negative features of the needle and syringe system, the topical absorption of medication transcutaneously through an occlusive patch was developed. However, both of these drug delivery systems have significant drawbacks. The human aversion to a needle injection has not abated during the nearly two centuries of its use. The variable systemic absorption of either a subcutaneous or intramuscular drug injection reduces drug efficacy and may increase the incidence of adverse patient responses. Depending upon the lipid or aqueous carrier fluid of the drug, the topically applied occlusive patch is plagued with variable absorption across an epidermal barrier. For patients who require local anesthesia over a large surface area of skin, neither the syringe/needle injections nor topical anesthetics are ideal. The syringe/needle “field” injections are often painful and may instill excessive amounts of the local anesthetic that may cause systemic toxicity. Topical anesthetics rarely provide the level of anesthesia required for skin related procedures.


The drug delivery device 200 depicted in FIG. 5 successfully addresses the limitations and drawbacks of other drug delivery systems. A drum/cylinder 202 depicted in FIG. 5 is supported by an axel/handle assembly 204 and rotated around a drum rotation component 206. The handle assembly 204 may further include a reservoir 208 of drugs to be delivered and a syringe plunger 210. The surface of the drum 202 is covered by an array of needles 212 of uniform length, which provide a uniform intradermal (or subdermal) injection depth with a more controlled volume of the drug injected into the skin of the patient. During operation, the syringe plunger 210 pushes the drug out of the reservoir 208 to be injected into a sealed injection chamber 214 inside the drum 202 via connecting tube 216. The drug is eventually delivered into the patient's skin at a uniform depth when the array of needles 212 is pushed into a patient's skin until the surface of the drum 202 hits the skin. Non-anesthetized skip area is avoided and a more uniform pattern of cutaneous anesthesia is created. The rolling drum application of the drug delivery device 200 also instills the local anesthetic faster with less discomfort to the patient.



FIGS. 6(a)-(c) depict alternative embodiments of a drug delivery device 300, where a flat array of fine needles 312 of uniform length positioned on manifold 310 can be utilized for drug delivery. In the examples of FIG. 6(a), syringe 302 in which drug for injection is contained can be plugged into a disposable adaptor 306 with handles, and a seal 308 can be utilized to ensure that the syringe 302 and the disposable adaptor 306 are securely coupled to each other. When the syringe plunger 304 is pushed, drug contained in syringe 302 is delivered from syringe 302 into the disposable adaptor 306. The drug is further delivered into the patient's skin through the flat array of fine needles 312 at a uniform depth when the array of needles 312 is pushed into a patient's skin until manifold 310 hits the skin. FIGS. 6(b)-(c) depict top and bottom views of the drug delivery device 300 with a flat array of fine needles 312, respectively.


The use of the drug delivery device 200 may have as many clinical applications as the number of pharmacological agents that require transcutaneous injection or absorption. For non-limiting examples, a few of the potential applications are the injection of local anesthetics, the injection of neuromodulators such as Botulinum toxin (Botox), the injection of insulin and the injection of replacement estrogens and corticosteroids.


In some embodiments, the syringe plunger 210 of the drug delivery device 200 can be powered by, for a non-limiting example, an electric motor. In some embodiments, a fluid pump (not shown) attached to an IV bag and tubing can be connected to the injection chamber 214 and/or the reservoir 208 for continuous injection. In some embodiments, the volume of the syringe plunger 210 in the drug delivery device 200 is calibrated and programmable.


The foregoing description of various embodiments of the invention has been presented for purposes of illustration and description. Various methods of the invention are applicable to variety of medical, dermatological and surgical methods including reconstructive and plastic surgery procedures and minimally invasive procedures. It is not intended to limit the invention to the precise forms disclosed. Many modifications, variations and different combinations of embodiments will be apparent to practitioners skilled in this art. Further, elements from one embodiment can be readily recombined with one or more elements from other embodiments.

Claims
  • 1. A system, comprising: a scalpet assembly comprising a scalpet array, wherein the scalpet array includes scalpets, wherein each scalpet comprises a cylindrical scalpet with a circular cross-section and a distal end configured to generate circular incisions including a diameter approximately in a range of 0.5 millimeters (mm) to 2.0 mm, wherein the scalpet array is configured to be deployed to a plurality of target sites to generate a plurality of incised skin pixels at the plurality of target sites; anda capture system configured to capture the plurality of incised skin pixels at the plurality of target sites.
  • 2. The system of claim 1, wherein the distal end of the scalpets includes a sharpened edge.
  • 3. The system of claim 1, wherein an interior region of the scalpets includes a hollow region.
  • 4. The system of claim 1, wherein the generation of the plurality of incised skin pixels includes generation of a plurality of skin defects configured to evoke neovascularization at the plurality of target sites.
  • 5. The system of claim 1, wherein the generation of the plurality of incised skin pixels includes generation of a plurality of skin defects configured to evoke a wound healing response at a recipient site.
  • 6. The system of claim 1, wherein the plurality of target sites includes at least one of a donor site and a recipient site.
  • 7. The system of claim 6, wherein the plurality of incised skin pixels is harvested at the donor site.
  • 8. The system of claim 7, wherein the generation of the plurality of incised skin pixels includes generation of a plurality of skin defects at the recipient site, wherein the plurality of skin defects is configured to receive a skin graft comprising the plurality of incised skin pixels from the plurality of target sites.
  • 9. The system of claim 8, wherein the capture system includes an adherent substrate configured to at least one of capture the plurality of incised skin pixels at the donor site and transfer the plurality of incised skin pixels to the recipient site.
  • 10. The system of claim 9, wherein the adherent substrate is configured to maintain relative positioning of the plurality of incised skin pixels during transfer to and application at the recipient site.
  • 11. The system of claim 9, wherein the adherent substrate is configured to apply the plurality of incised skin pixels to the skin defects at the recipient site.
  • 12. The system of claim 9, wherein the adherent substrate is configured to align the plurality of incised skin pixels with the skin defects at the recipient site.
  • 13. The system of claim 9, wherein the adherent substrate is configured as a bandage and to apply force to close the plurality of target sites, wherein the force includes a directional force configured to control a direction of the closure at the plurality of target sites.
  • 14. The system of claim 1, wherein the capture system includes an adherent substrate configured to capture the plurality of incised skin pixels.
  • 15. The system of claim 14, wherein the adherent substrate comprises at least one of a flexible substrate and a semi-porous membrane.
  • 16. The system of claim 1, wherein the capture system includes a vacuum system configured to evacuate tissue including the plurality of incised skin pixels from the plurality of target sites.
  • 17. The system of claim 1, wherein the capture system is coupled to the scalpet assembly.
  • 18. The system of claim 1, comprising at least one bandage configured for application at the plurality of target sites, wherein the at least one bandage is configured to apply force to close the plurality of target sites, wherein the force includes a directional force configured to control a direction of the closure at the plurality of target sites.
  • 19. The system of claim 1, comprising a powered component coupled to the scalpet assembly.
  • 20. The system of claim 19, wherein the powered component includes a rotational component configured to couple a rotational force to the scalpets.
  • 21. The system of claim 1, comprising a cutting member configured to transect the plurality of incised skin pixels.
RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 14/556,648, filed Dec. 1, 2014, now U.S. Pat. No. 9,987,473, which is a continuation of U.S. patent application Ser. No. 12/972,013, filed Dec. 17, 2010, now U.S. Pat. No. 8,900,181, which claims priority to U.S. Provisional Patent Application No. 61/288,141, filed Dec. 18, 2009, all of which are hereby incorporated herein by reference.

US Referenced Citations (192)
Number Name Date Kind
1610089 Heitler Dec 1926 A
3613242 Hill et al. Oct 1971 A
3820543 Vanjushin et al. Jun 1974 A
3867942 Bellantoni et al. Feb 1975 A
4018228 Goosen Apr 1977 A
4098278 Schwartz Jul 1978 A
4160453 Miller Jul 1979 A
4476864 Tezel Oct 1984 A
4542742 Winkelman et al. Sep 1985 A
4582640 Smestad et al. Apr 1986 A
4803075 Wallace et al. Feb 1989 A
4944737 Bloom Jul 1990 A
5123907 Romaine Jun 1992 A
5141513 Fortune et al. Aug 1992 A
5209755 Abrahan et al. May 1993 A
5415182 Chin et al. May 1995 A
5417683 Shiao May 1995 A
5570700 Vogeler Nov 1996 A
5578054 Arnold Nov 1996 A
5591444 Boss, Jr. Jan 1997 A
5643308 Markman Jul 1997 A
5665372 Boss, Jr. Sep 1997 A
5693064 Arnold Dec 1997 A
5827297 Boudjema Oct 1998 A
5858019 Ashraf Jan 1999 A
5871495 Mueller Feb 1999 A
5879326 Godshall et al. Mar 1999 A
5895403 Collinsworth Apr 1999 A
5922000 Chodorow Jul 1999 A
5928162 Giurtino et al. Jul 1999 A
5964729 Choi et al. Oct 1999 A
5970709 Tohji Oct 1999 A
5989278 Mueller Nov 1999 A
6027512 Bridges Feb 2000 A
6059807 Boudjema May 2000 A
6126615 Allen et al. Oct 2000 A
6432710 Boss, Jr. et al. Aug 2002 B1
6471712 Burres Oct 2002 B2
6497875 Sorrell et al. Dec 2002 B1
6572625 Rassman Jun 2003 B1
6585746 Gildenberg Jul 2003 B2
6589202 Powell Jul 2003 B1
6626865 Prisell Sep 2003 B1
6669685 Rizoiu et al. Dec 2003 B1
6997923 Anderson et al. Feb 2006 B2
7204828 Rosiello Apr 2007 B2
7261721 Feller Aug 2007 B2
7316822 Binette et al. Jan 2008 B2
7331953 Manstein et al. Feb 2008 B2
7354423 Zelickson et al. Apr 2008 B2
7412978 Keller Aug 2008 B1
7621933 Bodduluri et al. Nov 2009 B2
7625384 Eriksson Dec 2009 B2
7708746 Eriksson et al. May 2010 B2
7846465 Keller et al. Dec 2010 B1
7942153 Manstein et al. May 2011 B2
7962192 Bodduluri et al. Jun 2011 B2
7993310 Rosiello Aug 2011 B2
8062322 Rassman et al. Nov 2011 B2
8202279 Cole Jun 2012 B2
8211134 Oostman, Jr. Jul 2012 B2
8317804 Rassman et al. Nov 2012 B1
8486155 McAlister et al. Jul 2013 B2
8529883 Maslowski Sep 2013 B2
8535299 Giovannoli Sep 2013 B2
8540731 Kay Sep 2013 B2
8545489 Giovannoli Oct 2013 B2
8690863 Chan et al. Apr 2014 B2
8728819 Maslowski et al. May 2014 B2
8765121 Maslowski Jul 2014 B2
8900181 Knowlton Dec 2014 B2
8986324 Bodduluri et al. Mar 2015 B2
9005218 Harris Apr 2015 B2
9060803 Anderson et al. Jun 2015 B2
9095368 Umar et al. Aug 2015 B2
9351792 Manstein et al. May 2016 B2
9415075 Maslowski Aug 2016 B2
9439673 Austen Sep 2016 B2
9468459 Hall et al. Oct 2016 B2
9743949 Guiles et al. Aug 2017 B2
D797286 Ginggen et al. Sep 2017 S
9902937 Maslowski et al. Feb 2018 B2
10098914 Maslowski Oct 2018 B2
10117721 Tripathi et al. Nov 2018 B2
10219827 Knowlton et al. Mar 2019 B2
10251792 Levinson et al. Apr 2019 B2
10335190 Knowlton Jul 2019 B2
10368904 Knowlton Aug 2019 B2
20010053888 Athanasiou et al. Dec 2001 A1
20020052619 Transue May 2002 A1
20020088779 Neev et al. Jul 2002 A1
20020111563 Hall Aug 2002 A1
20020183688 Lastovich et al. Dec 2002 A1
20030036770 Markman Feb 2003 A1
20030069548 Connelly et al. Apr 2003 A1
20030216719 Debenedictis et al. Nov 2003 A1
20040082940 Black et al. Apr 2004 A1
20040087893 Kwon May 2004 A1
20040087992 Gartstein et al. May 2004 A1
20040175690 Mishra et al. Sep 2004 A1
20040210214 Knowlton Oct 2004 A1
20050049582 Debenedictis et al. Mar 2005 A1
20050154331 Christie et al. Jul 2005 A1
20050154431 Quistgaard et al. Jul 2005 A1
20050171504 Miller Aug 2005 A1
20050267506 Harris Dec 2005 A1
20050283141 Giovannoli Dec 2005 A1
20060051404 Yeshurun et al. Mar 2006 A1
20060155266 Manstein et al. Jul 2006 A1
20070038236 Cohen Feb 2007 A1
20070073217 James Mar 2007 A1
20070073327 Giovannoli Mar 2007 A1
20070179481 Frangineas et al. Aug 2007 A1
20070179516 Mishra et al. Aug 2007 A1
20070207131 Boss, Jr. et al. Sep 2007 A1
20070224173 Koullick et al. Sep 2007 A1
20070293884 Cole et al. Dec 2007 A9
20080172047 Altshuler et al. Jul 2008 A1
20080275378 Herndon Nov 2008 A1
20090048558 Del Vecchio Feb 2009 A1
20100114118 Harris May 2010 A1
20100121307 Lockard et al. May 2010 A1
20100204722 Gilsdorf Aug 2010 A1
20100303770 Maslowski et al. Dec 2010 A1
20110009860 Chornenky et al. Jan 2011 A1
20110077664 Schulz et al. Mar 2011 A1
20110177591 Iwatschenko et al. Jul 2011 A1
20110208089 Sundheimer et al. Aug 2011 A1
20110251602 Anderson et al. Oct 2011 A1
20110257588 Knowlton Oct 2011 A1
20110264115 Asrani et al. Oct 2011 A1
20110282239 Conlon et al. Nov 2011 A1
20110282382 McAlister et al. Nov 2011 A1
20110313429 Anderson et al. Dec 2011 A1
20120022510 Welches et al. Jan 2012 A1
20120035599 Sabir et al. Feb 2012 A1
20120041430 Anderson et al. Feb 2012 A1
20120219634 Maslowski et al. Aug 2012 A1
20120226214 Gurtner et al. Sep 2012 A1
20120271320 Hall et al. Oct 2012 A1
20120323139 Richardson Dec 2012 A1
20120323325 Fulton Dec 2012 A1
20130006168 Del Vecchio Jan 2013 A1
20130090669 Bellomo et al. Apr 2013 A1
20130096600 Wesley et al. Apr 2013 A1
20130204273 Sabir et al. Aug 2013 A1
20130236427 Pernock Sep 2013 A1
20130287286 Zingaretti et al. Oct 2013 A1
20130295061 Maslowski Nov 2013 A1
20130304090 Oostman, Jr. et al. Nov 2013 A1
20130345721 Menke et al. Dec 2013 A1
20140031801 Giovannoli Jan 2014 A1
20140099383 Maslowski et al. Apr 2014 A1
20140277055 Austen, Jr. Sep 2014 A1
20140296741 Austen Oct 2014 A1
20140303648 Knowlton Oct 2014 A1
20140343575 Andreani et al. Nov 2014 A1
20150018844 Harris Jan 2015 A1
20150173991 Anderson et al. Jun 2015 A1
20150201955 Sabir et al. Jul 2015 A1
20150216545 Anderson et al. Aug 2015 A1
20150230818 Knowlton Aug 2015 A1
20150238214 Anderson et al. Aug 2015 A1
20150250493 Umar Sep 2015 A1
20150366719 Levinson et al. Dec 2015 A1
20160008515 Stilwell et al. Jan 2016 A1
20160095592 Levinson et al. Apr 2016 A1
20160166272 Shiao Jun 2016 A1
20160192961 Ginggen et al. Jul 2016 A1
20160287281 Knowlton Oct 2016 A1
20160310157 Guiles et al. Oct 2016 A1
20160310158 Guiles et al. Oct 2016 A1
20160310159 Guiles et al. Oct 2016 A1
20160310444 Dobak, III Oct 2016 A1
20160317170 Knowlton Nov 2016 A1
20160317721 Ginggen et al. Nov 2016 A1
20160340651 Maslowski et al. Nov 2016 A1
20160367280 Austen Dec 2016 A1
20170042561 Hall et al. Feb 2017 A1
20170079824 Thompson Mar 2017 A1
20170296214 Knowlton Oct 2017 A1
20170333068 Knowlton Nov 2017 A1
20170367729 Ginggen et al. Dec 2017 A1
20180006300 Jeong et al. Jan 2018 A1
20180036029 Anderson et al. Feb 2018 A1
20180078278 Levinson et al. Mar 2018 A1
20180161056 Kim et al. Jun 2018 A1
20180325543 Skog et al. Nov 2018 A1
20180346878 Maslowski et al. Dec 2018 A1
20190015255 Gurtner et al. Jan 2019 A1
20190046777 Knowlton Feb 2019 A1
20190099199 Levinson et al. Apr 2019 A1
Foreign Referenced Citations (14)
Number Date Country
101530636 Feb 2012 CN
200303833 Aug 2003 KR
20080100795 Nov 2008 KR
014556 Jun 2001 WO
2005072181 Aug 2005 WO
2008002064 Jan 2008 WO
2009146068 Dec 2009 WO
2012103483 Aug 2012 WO
2012136904 Oct 2012 WO
2013013196 Jan 2013 WO
2013013199 Jan 2013 WO
2014028626 Feb 2014 WO
2014089488 Jun 2014 WO
2015051164 Apr 2015 WO
Non-Patent Literature Citations (65)
Entry
Ablaza V.J., et al., “An Alternative Treatment for the Split Skin-Graft Donor Site,” Aesthetic Plastic Surgery, 1997, vol. 21 (3), pp. 207-209.
Akan M., et al., “An Alternative Method to Minimize Pain in the Split-Thickness Skin Graft Donor Site,” Plastic and Reconstructive Surgery, Aug. 2002, vol. 111 (7), pp. 2243-2249.
Alguire P.C et al., “Skin Biopsy Techniques for the Internist,” Journal of General Internal Medicine, Jan. 1998, vol. 13 (1), pp. 46-54.
Andreassi A., et al., “Classification and Pathophysiology of Skin Grafts,” Clinics in Dermatology, 2005, vol. 23 (4), pp. 332-337.
Bello Y.M., et al., “Tissue-Engineered Skin, Current Status in Wound Healing,” American Journal Clinical Dermatology, 2001, vol. 2 (5), pp. 305-313.
Branski L.K., et al., “A Porcine Model of Full-Thickness Burn, Excision, and Skin Autographing,” Burns, 2008, vol. 34 (8), pp. 1119-1127.
Burns J.A., “Thermage: Monopolar Radiofrequency,” Aesthetic Surgery Journal, Nov./Dec. 2005, vol. 25 (6), pp. 638-642.
Cirodde A., et al., “Cultured Epithelial Autografts in Massive Burns: A Single-Center Retrospective Study with 63 Patients,” Burns, 2011, vol. 37 (6), pp. 964-972.
Clugston P.A., et al., “Cultured Epithelial Autografts: Three Years of Clinical Experience with Eighteen Patients,” Journal of Burn Care and Rehabilitation, 1991, vol. 12 (6), pp. 533-539.
Cooperman L.S., et al., “Injectable Collagen: A Six-Year Clinical Investigation,” Aesthetic Plastic Surgery, Jun. 1985, vol. 9 (2), pp. 145-151.
Dornseifer U., et al., “The Ideal Split-Thickness Skin Graft Donor Site Dressing: Rediscovery of Polyurethane Film,” Annals of Plastic Surgery, Aug. 2009, vol. 63 (2), pp. 198-200.
Dornseifer U., et al., “The Ideal Split-Thickness Skin Graft Donor-Site Dressing: A Clinical Comparative Trial of a Modified Polyurethane Dressing and Aquacel,” Plastic and Reconstructive Surgery, 2011, vol. 128 (4), pp. 918-924.
Elliot M., et al., “Initial Experience with Cultured Epithelial Autografts in Massively Burnt Patients,” ANZ Journal of Surgery, 2002, vol. 72 (11), pp. 893-895.
Extended European Search Report for Application No. EP05027935 dated Jun. 12, 2009, 4 pages.
Fischer J.P., et al., “Complications in Body Contouring Procedures: An Analysis of 1797 Patients from the 2005 to 2010 American College of Surgeons National Surgical Quality Improvement Program Databases,” Plastic and Reconstructive Surgery, 2013, vol. 132 (6), pp. 1411-1420.
Ford C.N., et al., “A Preliminary Study of Injectable Collagen in Human Vocal Fold Augmentation,” Otolaryngology—Head and Neck Surgery, Jan. 1986, vol. 94 (1), pp. 104-112.
Ford C.N., et al., “Autologous Collagen Vocal Fold Injection: A Preliminary Clinical Study,” Laryngoscope, Sep. 1995, vol. 105 (9 Pt 1), pp. 944-998.
Ford C.N., et al., “Clinical Experience with Injectable Collagen for Vocal Fold Augmentation,” Larynscope, Aug. 1986, vol. 96 (8), pp. 863-869.
Ford C.N., et al., “Role of Injectable Collagen in the Treatment of Glottic Insufficiency: A Study of 119 Patients,” The Annals of otology, Rhinology and Laryngology, Mar. 1992, vol. 101 (3), pp. 237-247.
Frey P., et al., “Subureteral Collagen Injection for the Endoscopic Treatment of Vesicoureteral Reflux in Children. Followup Study of 97 Treated Ureters and Histological Analysis of Collagen Implants,” The Journal of Urology, Aug. 1992, vol. 148 (2 Pt 2), pp. 718-723.
Giordano A., et al., “From the Laboratory Bench to the Patient's Bedside: An Update on Clinical Trials with Mesenchymal Stem Cells,” Department of Experimental Medicine of Biotechnology and Molecular Biology, Second University of Naples, Oct. 2006, 10 pages.
Greenwood J., et al., “Real-Time Demonstration of Split Skin Graft Inosculation and Integra Dermal Matrix Neovascularization Using Confocal Laser Scanning Microscopy,” Journal of Plastic Surgery, Aug. 2009, vol. 9, pp. e33.
Hallock G.G., “The Cosmetic Split-Thickness Skin Graft Donor Site,” Plastic and Reconstructive Surgery, 1999, vol. 104 (7), pp. 2286-2288.
Hansbrough W., et al., “Management of Skin-Grafted Burn Wounds with Xeroform and Layers of Dry Coarse-Mesh Gauze Dressing Results in Excellent Graft Take and Minimal Nursing Time,” Journal of Burn Care and Rehabilitation, 1995, vol. 16 (5), pp. 531-534.
Hazani R., et al., “Optimizing Aesthetic Results in Skin Grafting,” The American Surgeon, Feb. 2012, vol. 78 (2), pp. 151-154.
International Search Report and Written Opinion for Application No. PCT/US2017/017683, dated Jul. 27, 2017, 10 pages.
International Search Report and Written Opinion for Application No. PCT/US2017/030840, dated Oct. 3, 2017, 15 pages.
International Search Report and Written Opinion for Application No. PCT/US2018/017100, dated Sep. 12, 2018, 18 pages.
International Search Report and Written Opinion for Application No. PCT/US2018/32387, dated Jan. 7, 2019, 15 pages.
International Search Report and Written Opinion for Application No. PCT/US2019/037484, dated Jan. 7, 2020, 15 pages.
International Search Report and Written Opinion for Application No. PCT/US2013/073678, dated May 27, 2014, 18 pages.
International Search Report and Written Opinion for Application No. PCT/US2014/058886, dated Mar. 2015, 22 pages.
International Search Report and Written Opinion for Application No. PCT/US2015/047695, dated Jan. 28, 2016, 40 pages.
International Search Report and Written Opinion for Application No. PCT/US2015/047721, dated Feb. 3, 2016, 20 pages.
International Search Report and Written Opinion for Application No. PCT/US2016/016834, dated May 17, 2016, 11 pages.
Ito K., et al., “Biology of Fracture Healing,” AO Principles of Fracture Management, AO Foundation Publishing, Jan. 2013, 5 pages.
Jones L.M., “The Biobrane Stent,” Journal of Burn Care and Rehabilitation, 1998, vol. 19 (4), pp. 352-353.
Kaplan E.N., et al., “Clinical Utilization of Injectable Collagen,” Annals of Plastic Surgery, Jun. 1983, vol. 10 (6), pp. 437-451.
Klein A.W., et al., “Implantation Technics for Injectable Collagen,” Journal of the American Academy of Dermatology, Aug. 1983, vol. 9 (2), pp. 224-228.
Kogan L., et al., “Vertical (Two-Layer) Skin Grafting: New Reserves for Autologic Skin,” Annals of Plastic Surgery, 2003, vol. 50 (5), pp. 514-516.
Lee H., et al., “Outcomes of Sprayed Cultured Epithelial Autografts for Full-Thickness Wounds: A Single-Centre Experience,” Burns, 2012, vol. 38 (6), pp. 931-936.
Lindenblatt N., et al., “A New Model for Studying the Revascularization of Skin Grafts in Vivo: The Role of Angiogenesis,” Plastic and Reconstructive Surgery, 2008, vol. 122 (6), pp. 1669-1680.
Matton G., et al., “The History of Injectable Biomaterials and the Biology of Collagen,” Aesthetic Plastic Surgery, Jun. 1985, vol. 9 (2), pp. 133-140.
Mimoun M., et al., “The Scalp is an Advantageous Donor Site for Thin-Skin Grafts: A Report on 945 Harvested Samples,” Plastic and Reconstructive Surgery, 2006, vol. 118 (2), pp. 369-373.
Mottura A.A., et al., “Open Frontal Lift: A Conservative Approach,” Aesthetic Plastic Surgery, 2006, vol. 30 (4), pp. 381-389.
O'Connor K.W., et al., “Endoscopic Placement of Collagen at the Lower Esophageal Sphincter to Inhibit Gastroesophageal Reftux: a Pilot Study of 10 Medically Intractable Patients,” Gastrointestinal Endoscopy, 1988, vol. 34 (2), pp. 106-112.
Pallua N., et al., “The Lipo-Facelift: Merging the Face-Lift and Liposculpture: Eight Years Experience and a Preliminary Observational Study,” Aesthetic Plastic Surgery, 2013, vol. 37 (6), pp. 1107-1113.
Penington A.J., et al., “Skin Graft Failure Is Predicted by Waist-Hip Ratio: Marker for Metabolic Syndrome,” ANZ Journal of Surgery, 2007, vol. 77 (3), pp. 118-120.
Polder K.D., et al., “Radiofrequency: Thermage,” Facial Plastic Surgery Clinics of North America, 2011, vol. 19 (2), pp. 347-359.
Russe E et al., “Micro-Fractional, Direction Skin Tightening: A Porcine Model,” Lasers in Surgery and Medicine, Mar. 2016, vol. 48 (3), pp. 264-269.
Sheridan R.L., et al., “Initial Experience with a Composite Autologous Skin Substitute,” Burns, 2000, vol. 27 (5), pp. 421-424.
Shortliffe L.M., et al., “Treatment of Urinary Incontinence by the Periurethral Implantation of Glutaraldehyde Cross-Linked Collagen,” The Journal of Urology, Mar. 1989, vol. 141 (3), pp. 538-541.
Sklar L.R., et al., “Use of Transcutaneous Ultrasound for Lipolysis and Skin Tightening: A Review,” Aesthetic Plastic Surgery, 2014, vol. 38 (2), pp. 429-441.
Sukal S.A., et al., “Thermage: The Nonablative Radiofrequency for Rejuvenation,” Clinics in Dermatology, 2008, vol. 26 (6), pp. 602-607.
Supplementary European Search Report for Application No. EP14850567 dated May 4, 2017, 4 pages.
Supplementary European Search Report for Application No. EP15836045 dated Jan. 8, 2018, 7 pages.
Supplementary European Search Report for Application No. EP17750972 dated Sep. 13, 2019, 8 pages.
Supplementary European Search Report for Application No. EP17793252 dated Nov. 22, 2019, 7 pages.
Supplementary European Search Report for Application No. EP13859972, dated Jun. 10, 2016, 6 pages.
Thourani V.H., et al., “Factors Affecting Success of Split-Thickness Skin Grafts in the Modern Burn Unit,” The Journal of Trauma, Mar. 2003, vol. 54 (3), pp. 562-568.
Wells M.D., et al., “A New Method of Skin-Graft Stabilization: The Reston Technique,” Annals of Plastic Surgery, 1995, vol. 34 (5), pp. 554-556.
Wendt J.R., et al., “Long-Term Survival of Human Skin Allografts in Patients with Immunosuppression,” Plastic and Reconstructive Surgery, Apr. 2004, vol. 133 (5), pp. 1347-1354.
Williamson J. S., et al., “Cultured Epithelial Autograft: Five Years of Clinical Experience with Twenty-Eight Patients,” The Journal of Trauma, Aug. 1995, vol. 39 (2), pp. 309-319.
Wood F.M., et al., “The Use of Cultured Epithelial Autograft in the Treatment of Major Burn Injuries: A Critical Review of the Literature,” Burns, 2006, vol. 32 (4), pp. 395-401.
Zuber T.J., “Fusiform Exision,” American Family Physician, Apr. 2003, vol. 67 (7), pp. 1539-1544.
Related Publications (1)
Number Date Country
20190134365 A1 May 2019 US
Provisional Applications (1)
Number Date Country
61288141 Dec 2009 US
Continuations (2)
Number Date Country
Parent 14556648 Dec 2014 US
Child 15997316 US
Parent 12972013 Dec 2010 US
Child 14556648 US